Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Decitabine and CD19 PD-1/CD28 CAR-T in R/R DLBCL
NCT04850560Phase 1Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2021
- Primary completion
- May 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PD1-CD19-CART in diffuse large B-cell lymphoma (DLBCL), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Objective Response Rate at 3 months. Status: unknown.
02
Drugs
PD1-CD19-CART
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04850560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04850560.